Real-world data of the effects of serum 25(OH)D and plasma fatty acids on breast and stomach tumors：A cross-sectional study

Objective: To investigate the correlation between serum 25(OH)D and plasma fatty acid levels and the clinical stage, tumor markers, histopathology and lymph node metastasis of patients with solid tumors, so as to further understand the potential impact of vitamin D and fatty acids on breast and stomach tumors. Methods A real world study, cross sectional study was conducted on patients with breast malignant tumor, benign breast tumor and gastric malignant tumor who were treated in Liaoning Cancer Hospital & Institute, from April 2020 to May 2021. The general clinical data of the patients, the laboratory data of serum vitamin D and plasma fatty acid levels were collected, and the effects of serum vitamin D and plasma fatty acid levels on solid tumors were statistically analyzed. Results The serum 25 (OH) D level and plasma fatty acid level of tumor patients were abnormal compared with their corresponding normal standard values. The expression level of 25 (OH) D in breast malignant tumors was significantly different according to tumor stage and molecular classification (P < 0.05), indicating that the pathological features such as tumor stage and molecular classification of breast cancer may be related to the expression level of serum 25 (OH) D. Multivariate analysis showed that carcinoembryonic antigen was a significant difference between breast malignant tumors and benign breast tumors, and 25 (OH) D and eicosapentaenoic acid (DPA) were significant differences between breast malignant tumors and benign breast tumors (P < 0.1). Conclusion Vitamin D deficiency and deficiency are common in tumor patients. The level of serum 25 (OH) D is correlated with the course of breast tumor, tumor stage and molecular classification. 25 (OH) D is a significant difference between breast malignant tumor and breast benign tumor. There is abnormal level of plasma free fatty acid in tumor patients. DPA is a significant difference between breast malignant tumor and benign breast tumor, which may be related to the pathological degree of breast tumor.